A General-Equilibrium Analysis of Public Policy for Pharmaceutical Prices
Retail sales of prescription drugs totaled $154.5 billion in 2001 and will likely exceed $400 billion by 2010. This paper contrasts the welfare and distributional effects of the current patented-monopoly system with those of (1) a price ceiling on pharmaceutical products and (2) a universal insurance program covering pharmaceutical purchases. We use a version of the Kelton and Wallace (1995) two-good, general-equilibrium monopoly model in which a license is required to produce one good. Individuals have heterogeneous preferences, but are otherwise identical. Results indicate potential welfare gains for both the price-ceiling and universal-insurance policies, with very distinct distributional effects. Copyright 2007 Blackwell Publishing, Inc..
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Volume (Year): 9 (2007)
Issue (Month): 2 (04)
|Contact details of provider:|| Web page: http://www.blackwellpublishing.com/journal.asp?ref=1097-3923|
More information through EDIRC
|Order Information:||Web: http://www.blackwellpublishing.com/subs.asp?ref=1097-3923|
References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Xiangkang Yin, 2000.
"A tractable alternative to Cobb-Douglas utility for imperfect competition,"
2000.10, School of Economics, La Trobe University.
- Yin, Xiangkang, 2001. "A Tractable Alternative to Cobb-Douglas Utility for Imperfect Competition," Australian Economic Papers, Wiley Blackwell, vol. 40(1), pages 14-21, March.
- Daron Acemoglu & Joshua Linn, 2003.
"Market Size in Innovation: Theory and Evidence From the Pharmaceutical Industry,"
NBER Working Papers
10038, National Bureau of Economic Research, Inc.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," The Quarterly Journal of Economics, MIT Press, vol. 119(3), pages 1049-1090, August.
- Daron Acemoglu & Joshua Linn, 2004. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry," Levine's Working Paper Archive 228400000000000002, David K. Levine.
- Erik Canton & Ed Westerhout, 1999. "A model for the Dutch pharmaceutical market," Health Economics, John Wiley & Sons, Ltd., vol. 8(5), pages 391-402.
- repec:ltr:wpaper:1999.04 is not listed on IDEAS
- Xiangkang Yin, 1999.
"A Model of Shareholder Discounts,"
1999.04, School of Economics, La Trobe University.
- Bednarek, Heather L & Pecchenino, Rowena A, 2002.
" A Macroeconomic Analysis of Publicly Funded Health Care,"
Journal of Public Economic Theory,
Association for Public Economic Theory, vol. 4(2), pages 243-70.
- Bednarek, H.L. & Pecchenino, R.A., 1999. "A Macroeconomic Analysis of Publicly Funded Healthcare," Papers 9905, Michigan State - Econometrics and Economic Theory.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G., 2003. "The price of innovation: new estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 151-185, March.
- Amy Finkelstein, 2003. "Health Policy and Technological Change: Evidence from the Vaccine Industry," NBER Working Papers 9460, National Bureau of Economic Research, Inc.
- Cowling, Keith & Mueller, Dennis C, 1978. "The Social Costs of Monopoly Power," Economic Journal, Royal Economic Society, vol. 88(352), pages 727-48, December.
When requesting a correction, please mention this item's handle: RePEc:bla:jpbect:v:9:y:2007:i:2:p:285-318. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Wiley-Blackwell Digital Licensing)or (Christopher F. Baum)
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.